BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells

Journal of the National Cancer Institute

Volumn 92, Issue 2, 2000, Pages 112-120

  Brinkman, Arend ^a   Van Der Flier, Silvia ^b   Kok, Elisabeth M ^b   Dorssers, Lambert C J ^b  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; PROTEIN P130; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER GROWTH; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE ACTIVATION; GENE LOCATION; GENE LOCUS; GENE OVEREXPRESSION; HORMONAL REGULATION; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE HOMOLOGY;

EID: 0034684997     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.2.112     Document Type: Article

References (85)

1. Henderson BE, Ross R, Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1988;48:246-53.
2. King RJ, William L. McGuire Memorial Symposium. Estrogen and progestin effects in human breast carcinogenesis. Breast Cancer Res Treat 1993;27:3-15.
3. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988;240:889-95.
4. Truss M, Beato M. Steroid hormone receptors: interaction with deoxyribonucleic acid and transcription factors. Endocr Rev 1993;14:459-79.
5. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83: 835-9.
6. Beato M, Sanchez-Pacheco A. Interaction of steroid hormone receptors with the transcription initiation complex. Endocr Rev 1996;17:587-609.
7. Horwitz KB, Wei LL, Sedlacek SM, D'Arville CN. Progestin action and progesterone receptor structure in human breast cancer: a review. Recent Prog Horm Res 1985;41:249-316.
8. Foekens JA, Rio MC, Seguin P, Van Putten WL, Fauque J, Nap M, et al. Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 1990;50:3832-7.
9. Clarke RB, Howell A, Potten CS, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997;57:4987-91.
10. Jordan VC. Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res Treat 1994;31:41-52.
11. Wolf DM, Fuqua SA. Mechanisms of action of antiestrogens. Cancer Treat Rev 1995;21:247-71.
12. Katzenellenbogen BS, Montano MM, Ekena K, Herman ME, McInerney EM, William L. McGuire Memorial Lecture. Antiestrogens: mechanisms of action and resistance in breast cancer. Breast Cancer Res Treat 1997;44: 23-38.
13. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997;389:753-8.
14. Reese JC, Katzenellenbogen BS. Examination of the DNA-binding ability of ER in whole cells: implications for hormone-independent transactivation and the actions of antiestrogens. Mol Cell Biol 1992;12:4531-8.
15. Parker MG. Action of "p~ure" ant estrogens in inhibiting ER action. Breast Cancer Res Treat 1993;26:131-7.
16. Sutherland RL, Lee CS, Feldman RS, Musgrove EA. Regulation of breast cancer cell cycle progression by growth factors, steroids and steroid antagonists. J Ster Biochem Mol B ol 1992;41:315-21.
17. Watts CK, Brady A. Sarcevic B, DeFazio A, Musgrove EA, Sutherland RL. Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol 1995;9: 1804-13.
18. Guvakova MA, Surmacz E. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res 1997;57:2606-10.
19. Jordan VC, Murphy CS. Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev 1990;11:578-610.
20. Musgrove EA, Hamilton JA, Lee CS, Sweeney KJ, Watts CK, Sutherland RL. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 1993;13:3577-87.
21. Horwitz KB, McGuire WL, Pearson OH, Segaloff A. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 1975; 189:726-7.
22. Pritchard KI, Sutherland DJ. The use of endocrine therapy. Hematol Oncol Clin North Am 1989;3:765-805.
23. Santen RJ, Manni A. Harvey H, Redmond C. Endocrine treatment of breast cancer in women. Endocr Rev 1990;11:221-65.
24. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 Randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-15; 71-85.
25. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351: 1451-67.
26. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995;13:513-29.
27. Foekens JA, Schmitt M, Van Putten WL, Peters HA, Kramer MD, Janicke F, et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 1994;12:1648-58.
28. Osborne CK, Coronado E, Allred DC, Wiebe V, DeGregorio M. Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 1991;83:1477-82.
29. Johnston SR, Haynes BP, Smith IE, Jarman M, Sacks NP, Ebbs SR, et al. Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet 1993;342:1521-2.
30. Daffada AA, Johnston SR, Smith IE, Detre S, King N, Dowsett M. Exon 5 deletion variant ER messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer. Cancer Res 1995;55:288-93.
31. Fuqua SA, Wolf DM. Molecular aspects of estrogen receptor variants in breast cancer. Breast Cancer Res Treat 1995;35:233-41.
32. Murphy LC, Hilsenbeck SG, Dotzlaw H, Fuqua SA. Relationship of clone 4 estrogen receptor variant messenger RNA expression to some known prognostic variables in human breast cancer. Clin Cancer Res 1995;1: 155-9.
33. Clarke R, Dickson RB, Lippman ME. Hormonal aspects of breast cancer. Growth factors, drugs and stromal interactions. Crit Rev Oncol Hematol 1992;12:1-23.
34. Dorssers LC, Van Agthoven T, Sieuwerts AM. Genetic mechanisms involved in progression to hormone independence of human breast cancer. In: Berns PM, Romijn JC, Schroeder FH, editors. Mechanisms of progression to hormone-independent growth of breast and prostatic cancer. Carnforth (U.K.): Parthenon Publishing Group Ltd; 1991. p. 169-82.
35. Clarke R, Thompson EW, Leonessa F, Lippman J, McGarvey M, Frandsen TL, et al. Hormone resistance, invasiveness, and metastatic potential in breast cancer. Breast Cancer Res Treat 1993;24:227-39.
36. Dorssers LC, Van Agthoven T, Dekker A, Van Agthoven TL, Kok EM. Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: identification of bcar-1, a common integration site. Mol Endocrinol 1993;7:870-8.
37. Dorssers LC, Veldscholte J. Identification of a novel breast-cancer-anti-estrogen-resistance (BCAR2) locus by cell-fusion-mediated gene transfer in human breast-cancer cells. Int J Cancer 1997;72:700-5.
38. Van Agthoven T, Van Agthoven TL, Portengen H, Foekens JA, Dorssers LC. Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. Cancer Res 1992;52:5082-8.
39. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. BioTechniques 1989;7:980-90.
40. Van den Ouweland AM, Breuer ML, Steenbergh PH, Schalken JA, Bloemers HP, Van de Ven WJ. Comparative analysis of the human and feline c-sis proto-oncogenes: identification of 5′ human c-sis coding sequences that are not homologous to the transforming gene of simian sarcoma virus. Biochim Biophys Acta 1985;825:140-7.
41. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. New York (NY): Cold Spring Harbor Press; 1989.
42. Van Agthoven T, Van Agthoven TL, Dekker A, Van der Spek PJ, Vreede L, Dorssers LC. Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells. EMBO J 1998;17:2799-808.
43. Van Agthoven T, Van Agthoven TL, Dekker A, Foekens JA, Dorssers LC. Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations. Mol Endocrinol 1994;8:1474-83.
44. Sander EE, van Delft S, ten Klooster JP, Reid T, van der Kammen RA, Michiels F, et al. Matrix-dependent Tiam1/Rac signaling in epithelial cells promotes either cell-cell adhesion or cell migration and is regulated by phosphatidylinositol 3-kinase. J Cell Biol 1998;143:1385-98.
45. van der Flier S, Brinkman A, Look MP, Kok EM, Meijer-van Gelder ME, Klijn GM, et al. Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. J Natl Cancer Inst 2000;92: 000-000.
46. Sakai R, Iwamatsu A, Hirano N, Ogawa S, Tanaka T, Mano H, et al. A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation-dependent manner. EMBO J 1994; 13:3748-56.
47. Kozak M. An analysis of vertebrate mRNA sequences: intimations of translational control. J Cell Biol 1991;115:887-903.
48. Cas to SH2 and SH3 domains of Src kinase. J Biol Chem 1996;271:8959-65.
49. Cas. Proc Natl Acad Sei USA 1995;92:10678-82.
50. Callen DF, Lane SA, Kozman H, Kremmidiotis G, Whitmore SA, Lowenstein M, et al. Integration of transcript and genetic maps of chromosome 16 at near-1-Mb resolution: demonstration of a "hot spot" for recombination at 16p12. Genomics 1995;29:503-11.
51. cas, and Nck adaptor proteins. Mol Cell Biol 1997;17:1702-13.
52. Liu F, Sells MA, Chernoff J. Transformation suppression by protein tyrosine phosphatase 1B requires a functional SH3 ligand. Mol Cell Biol 1998; 18:250-9.
53. Blaukat A, Ivankovic-Dikic I, Gronroos E, Dolfi F, Tokiwa G, Vuori K, et al. Adaptor proteins grb2 and crk couple pyk2 with activation of specific mitogen-activated protein kinase cascades. J Biol Chem 1999;274: 14893-901.
54. Lu Y, Brush J, Stewart TA. NSP1 defines a novel family of adaptor proteins linking integrin and tyrosine kinase receptors to the c-Jun N-terminal kinase/stress-activated protein kinase signaling pathway. J Biol Chem 1999;274:10047-52.
55. Jonkers J, Berns A. Retroviral insertional mutagenesis as a strategy to identify cancer genes. Biochim Biophys Acta Rev Cancer 1996;1287:29-57.
56. Sakai R, Iwamatsu A, Hirano N, Ogawa S, Tanaka T, Nishida J, et al. Characterization, partial purification, and peptide sequencing of p130, the main phosphoprotein associated with v-Crk oncoprotein. J Biol Chem 1994;269:32740-6.
57. CAS. Mol Cell Biol 1995; 15:6513-25.
58. Honda H, Oda H, Nakamoto T, Honda Z, Sakai R, Suzuki T, et al. Cardiovascular anomaly, impaired actin bundling and resistance to Src-induced transformation in mice lacking p130Cas. Nat Genet 1998;19:361-5.
59. Cas, a substrate associated with v-Src and v-Crk, localizes to focal adhesions and binds to focal adhesion kinase. J Biol Chem 1996;271:13649-55.
60. CAS to focal adhesions. Mol Cell Biol 1997;17:3884-97.
61. Cas, a Src homology 3-containing molecule having multiple Src homology 2-binding motifs. J Biol Chem 1995;270:15398-402.
62. cas signaling complex formation upon integrin-mediated cell adhesion: a role for Src family kinases. Mol Cell Biol 1996;16:2606-13.
63. Howe A, Aplin AE, Alahari SK, Juliano RL. Integrin signaling and cell growth control. Curr Opin Cell Biol 1998;10:220-31.
64. Schlaepfer DD, Hunter T. Integrin signalling and tyrosine phosphorylation: just the FAKs? Trends Cell Biol 1998;8:151-7.
65. Cas. Involvement of phosphatidylinositol 3′-kinase and actin cytoskeleton. J Biol Chem 1997;272:25993-8.
66. Rozengurt EV. Gastrointestinal peptide signaling through tyrosine phosphorylation of focal adhesion proteins. Am J Physiol 1998;275:G177-82.
67. Sorokin A, Reed E. Insulin stimulates the tyrosine dephosphorylation of docking protein p130cas (Crk-associated substrate), promoting the switch of the adaptor protein crk from p130cas to newly phosphorylated insulin receptor substrate-1. Biochem J 1998;334:595-600.
68. Murakami H, Iwashita T, Asai N, Iwata Y, Narumiya S, Takahashi M. Rho-dependent and -independent tyrosine phosphorylation of focal adhesion kinase, paxillin and p130Cas mediated by Ret kinase. Oncogene 1999: 18:1975-82.
69. HEF1, a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells. J Biol Chem 1997;272:4230-6.
70. Cas as a mediator of focal adhesion kinase-promoted cell migration. J Cell Biol 1998;140:211-21.
71. Klemke RL, Leng J, Molander R, Brooks PC, Vuori K, Cheresh DA. CAS/Crk coupling serves as a "molecular switch" for induction of cell migration. J Cell Biol 1998;140:961-72.
72. Tamura M, Gu J, Takino T, Yamada KM. Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res 1999;59:442-9.
73. Cas as a substrate of Yersinia YopH (Yop51), a bacterial protein tyrosine phosphatase that translocates into mammalian cells and targets focal adhesions. EMBO J 1997;16: 2730-44.
74. Cas and FAK, and the associated accumulation of these proteins in peripheral focal adhesions. EMBO J 1997;16:2307-18.
75. Pawson T. Scott JD. Signaling through scaffold, anchoring, and adaptor proteins. Science 1997;278:2075-80.
76. cas-like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in Saccharomyces cerevisiae. Mol Cell Biol 1996;16:3327-37.
77. Minegishi M, Tachibana K, Sato T, Iwata S, Nojima Y, Morimoto C. Structure and function of Cas-L, a 105-kD Crk-associated substrate-related protein that is involved in β1 integrin-mediated signaling in lymphocytes. J Exp Med 1996;184:1365-75.
78. Ishino M, Ohba T, Sasaki H, Sasaki T. Molecular cloning of a cDNA encoding a phosphoprotein, Efs, which contains a Src homology 3 domain and associates with Fyn. Oncogene 1995;11:2331-8.
79. Cas-related protein. Sin. Genes Dev 1996;10:1341-55.
80. Law SF, Zhang YZ, Klein-Szanto AJ, Golemis EA. Cell cycle-regulated processing of HEF1 to multiple protein forms differentially targeted to multiple subcellular compartments. Mol Cell Biol 1998;18:3540-51.
81. Cas. J Biol Chem 1997; 272:228-32.
82. cas; a novel mechanism of protein tyrosine phosphatase substrate recognition. Oncogene 1997;15: 877-85.
83. Ohba T, Ishino M, Aoto H, Sasaki T. Interaction of two proline-rich sequences of cell adhesion kinase beta with SH3 domains of p130Cas-related proteins and a GTPase-activating protein. Graf. Biochem J 1998;330: 1249-54.
84. Burnham MR, Harte MT, Richardson A, Parsons JT, Bouton AH. The identification of p130cas-binding proteins and their role in cellular transformation. Oncogene 1996;12:2467-72.
85. cas with Crk and Grb2 adaptor proteins. Oncogene 1996;12:2491-8.